Nothing Special   »   [go: up one dir, main page]

WO1989009209A1 - Piperidine ring modified phencyclidine analogs as anticonvulsants - Google Patents

Piperidine ring modified phencyclidine analogs as anticonvulsants Download PDF

Info

Publication number
WO1989009209A1
WO1989009209A1 PCT/US1989/001229 US8901229W WO8909209A1 WO 1989009209 A1 WO1989009209 A1 WO 1989009209A1 US 8901229 W US8901229 W US 8901229W WO 8909209 A1 WO8909209 A1 WO 8909209A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compounds
formula
hydrogen
seizures
Prior art date
Application number
PCT/US1989/001229
Other languages
French (fr)
Inventor
Michael A. Rogawski
Kenner Rice
Arthur E. Jacobson
Andrew Thurkauf
Original Assignee
Marion Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Laboratories, Inc. filed Critical Marion Laboratories, Inc.
Publication of WO1989009209A1 publication Critical patent/WO1989009209A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Definitions

  • the present invention relates to improvements in epilepsy therapy, and more particularly to compounds useful in the treatment of epilepsy and control of epileptic seizures.
  • Epilepsy is a disorder characterized by recurrent seizures, each of which consists of a sudden, excessive discharge of cerebral neurons resulting in transient neurological impairment. Seizures can affect a localized area of cerebral tissues, i.e. a partial seizure, or may involve wide areas of both cerebral hemispheres, i.e. a generalized seizure. Both types of seizures may be disabling and can have potentially serious consequences, although generalized seizures are more often associated with injury. Most patients are treated by chronic drug therapy and, in certain intractable cases, by surgical removal of the affected brain tissue. Drug treatment of epilepsy is intended to prevent the occurrence of seizures, but does not cure the underlying brain dysfunction. In practice, some patients obtain a complete relief from seizures, others experience a diminution in the frequency or severity of seizures, and some patients do not respond.
  • Several drugs are currently in use for chronic prophylaxis against epileptic seizures. These compounds include phenobarbital, phenytoin, carbamazepine, primidone, valproic acid, ethosuximide, and clonazepam. Of these compounds, only the first four are effective and widely in use in the treatment of partial seizures. Valproic acid may be effective in treating partial seizures, although it is not approved or in widespread use for this treatment. All currently available antiepileptic drugs fail to control seizures in some patients. In those patients who respond, adverse drug effects may limit the patient to a suboptimal dose, or may prevent use of the drug. These adverse effects include dose dependent side effects and rare allergic or idiosyncratic reactions.
  • Phenobarbital may cause motor impairment including ataxia (unsteadiness), drowsiness, fatigue, and cognitive impairment. Phenytoin may cause ataxia, coarsening of the facial features, gingival hyperplasia, and hirsutism. Carbamazepine may cause ataxia, nausea and vomiting, and drowsiness. Primidone is metabolized to phenobarbital and phenylethylmalonamide, and has similar side effects to phenobarbital. In addition to these common side effects, all anticonvulsant drugs may cause rare idiosyncratic reactions, including serious blood and liver disorders, serious skin or integumentary disorders, or nerve damage (peripheral neuropathy).
  • Phencyclidine commonly known as PCP
  • PCP is currently a major drug of abuse in the United States. In recent years, it has received widespread attention because of the violent, homicidal and suicidal behavior of some of its users. Moreover, phencyclidine is one of the most entertaining psychotropic drugs, as the psychosis it elicits may provide the best available drug model of schizophrenia.
  • R 1 and R 2 are hydrogen or alkyl radicals, the sura of the carbon atoms in the alkyl groups being less than 5, or wherein R 1 and R 2 together represent a polymethylene group containing 4 to 6 carbon atoms.
  • R 1 and R 2 are said to be useful for producing varying degrees of depression on the central nervous sys tem , such as euphoria , sedat ion , analges ia , and anesthesia. There is no disclosure that these compounds can be used as anticonvulsants.
  • R 1 is hydrogen or lower alkyl
  • R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen, halogen, hydroxyl, lower alkyl, aralkoxy, or alkoxy, and wherein two adjacent groups R 2 - R 6 may together form a methylenedioxy group
  • X is lower alkylene which may be substituted by hydroxyl and/or keto groups and/or interrupted by a hetero atom
  • R 7 is hydrogen or lower alkyl
  • n is 2 or 3.
  • the compounds are said to be coronary artery dilating agents.
  • N is 1 or 3
  • Y is OH, R 1 COO-, R 2 R 3 NCOO-, or R4O, whereby R 1 is an alkyl group or a possibly substituted phenyl group, R 2 is an alkyl, phenethyl, benzyl, or phenyl group, R 3 is H or an alkyl group, and R 4 is an allyl or benzyl group, and R is an alkyl, hydroxyalkyl, dimethylaminoalkyl, or methylthioalkyl group or alkenyl group.
  • the compounds are said to be useful for treatment of disorders in the central nervous system, and are said to have dopaminergic properties.
  • R 1 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms, CH 2 -alkenyl wherein alkenyl is from 2 to 4 carbon atoms, cycloalkyl of from 3 to 6 carbon atoms, cycloalkylmethyl of from 3 to 6 carbon atoms;
  • R 2 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms;
  • Y is a variable consisting of alkyl of from 1 to 4 carbon atoms;
  • R 5 is a variable consisting of hydrogen and alkyl of from 1 to 4 carbon atoms;
  • R 4 is a variable consisting of alkyl of from 1 to 4 carbon atoms, CH 2 -alkenyl wherein alkenyl is of from 2 to 4 carbon atoms.
  • the compounds are said to be useful in relieving pain in humans and animals.
  • the compounds of the present invention are modifications of PCP wherein the piperidine ring is modified, and have the following formulae:
  • R 1 and R 2 may be hydrogen or lower alkyl, such as methyl, ethyl, propyl, isopropyl, or butyl or ( unsaturated) lower alkylene, or R 1 and R 2 may form with the nitrogen a three- to seven-membered ring with or without unsaturation, and R 3 and R 4 can be selected from the group consisting of hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, and halogen, i.e. chlorine, bromine or fluorine.
  • ring A may be a ring of from 5 to 8 carbon atoms.
  • the compounds of the present invention have anticonvulsant activity and, at effective doses, no toxicity (ataxia) has been observed.
  • the compounds of the present invention thus are superior to the presently available compounds for seizure prophylaxis in patients who fail to respond or who have unacceptable adverse reactions to presently available drugs.
  • the compounds of the present invention have been found to protect laboratory animals from seizures with little neurotoxicity.
  • the compounds were active in the maximal electroshock (MES) test, which determines the ability of a compound to prevent the spread of seizures, and is therefore a test for efficacy against partial seizures, i.e. those that begin locally in an area of abnormal cerebral cortex and subsequently spread to adjacent areas, often resulting in a generalized seizure.
  • Partial seizures are believed to be the most common type of seizure and to be responsible for many generalized seizures.
  • the compounds of the present invention are modifications of phencyclidine, compound I, below, and involve changes in the piperidine ring.
  • R 1 and R 2 may be hydrogen or lower alkyl, such as methyl, ethyl, propyl, isopropyl, or butyl, or (unsaturated) lower alkylene, or R 1 and R 2 may form a three-to-seven membered ring with nitrogen.
  • R 3 and R 4 can be hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, or halogen (Cl, Br, or F).
  • ring A may contain from 5 to 8 carbon atoms.
  • phenylcycloheptylamines have been found to be particularly useful in treating epilepsy.
  • the compounds of the present invention may be in the form of any pharmaceutically acceptable acid addition salt, i.e. any moiety which is non-toxic and makes the base compound soluble.
  • acid addition salts are hydrochloric acid, phosphoric acid, sulfuric acid, methanesulfonic acid, fumaric acid, and the like.
  • the base compound may be used.
  • Compound II was prepared by the addition of phenylmagnesium bromide to 1-(1-cyanocyclohexyl)-1,2,3,6-tetrahydropyridine.
  • the 1-(1-cyanocyclohexyl)-1,2,3,6-tetrahydropyridine was prepared by the acid catalyzed condensation of cyclohexanone, 1,2,3,6-tetrahydropyridine and potassium cyanide.
  • Compound II but not its utility, is known from M. R. Kazlowski, R. G. Browne and F. J. Vinick, Pharmacology Biochemistry & Behavior 25: 1051-1058 (1986).
  • the hydrochloride salt of compound II is a free flowing white powder with a melting point of 217- 218oC.
  • the molecular weight of the hydrochloride of compound II is 278.
  • Compound III was prepared in a three step synthesis from 3-(R)methylcyclohexanone. Phenylmagnesium bromide was condensed with 3-(R)- methylcyclohexanone to give a mixture of isomeric tertiary alcohols. These alcohols were reacted with sodium azide in the presence of trifluoroacetic acid to give the corresponding 1-azido-1-phenyl-3-(R)- methylcyclohexanes. The azides were reduced to the tertiary amines, and compound III was separated from IV by crystallization of fumarate salt. The fumarate salt of compound III is a free flowing white powder with a melting point of 230-231°C and a molecular weight of 305.
  • Compound VIII was prepared in a three step synthesis from cyclohexanone. 3-Methylphenylmagnesium bromide was condensed with cyclohexanone to give 1-(3-methylphenyl)cyclohexanol which in turn was reacted with sodium azide in the presence of trifluoroacetic acid to give the corresponding 1-azido-1-(3-methylphenyl)cyclohexane. The azide was then reduced to the tertiary amine VIII.
  • Compound IX was prepared by nitration of compound I with nitric acid according to the method of P. Y. Johnson, R. Pan, J. Q. Wen and C. J. Halfman, J. Org. Chem. 46: 2049-2054 (1981).
  • Compound X was prepared in the same manner as III except that cycloheptanone was used as the starting material instead of 3-(R)-methylcyclohexanone.
  • mice were injected intraperitoneally with the drugs indicated (dissolved in aqueous 0.9% sodium chloride solution) and tested 30 min later. Seizure protection indicates number of animals failing to exhibit hind-limb tonic extension in response to a 200 msec electrical stimulus (50 mA; 60 Hz) applied via corneal electrodes primed with 0.9% sodium chloride solution. Animals not treated with the vehicle solution ("control animals”) all exhibit hind-limb extension. Toxicity indicates number of animals unable to maintain equilibrium for 1 min when placed on a knurled rod rotating at 6 revolutions per min. Control animals are all able to maintain equilibrium. Data is expressed as number of animals showing effect/total number of animals tested.
  • the toxic dose (TD 50 ) for 50% of animals at the peak of the toxic effect, and the MES protective dose (ED 50 ) for 50% of the animals at the peak of the seizure protective effect were determined by probit analysis. The date are reported in mg/kg.
  • the compounds of the present invention may be administered as the bases, or may be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts is intended to include salts with pharmaceutically acceptable acids such as hydrochloric, sulfuric, acetic, phosphoric, methanesulfonic, fumaric, and the like.
  • compositions for treating epilepsy or other convulsions within the scope of the present invention include compositions wherein the active ingredient compound is contained in an effective amount to achieve its intended purpose. Determination of the effective amount is, of course, within the skill of the art. However, the compounds of the present invention are generally effective in preventing seizures when administered in dosa ⁇ es of from about 1 mg/kg of body weight to about 100 mg/kg of body weight, it being understood that individual dosages will vary with the individual response of the patient.
  • these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations particularly those which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, contain from about 0.1 to about 99 percent ,by weight of active ingredient, together with the excipient.
  • compositions of the present invention are manufactured in a conventional manner, for example, by means of conventional mixing, granulating, dragee-making, or dissolving processes.
  • pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired or necessary to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using for example maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone.
  • fillers such as sugars, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using for example maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropy
  • disintegrating agents may be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Slow or extended release compositions may also be formulated.
  • Dragee cores are provided with suitable coatings which, if desired, may be resistant to gastric juices.
  • suitable coatings which, if desired, may be resistant to gastric juices.
  • concentrated sugar solutions may be used, which may optionally contain gum Arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as acetyl-cellulose phthalate or hydroxypropylmethylcellulose phthalate, are used.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize different combinations of active compound doses.
  • Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • compositions which can be used rectally include, for example, suppositories, which consist of a combination of the active compounds with a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triclycerides, paraffin hydrocarbons, polyethylene glycols, and higher alkanols.
  • gelatin rectal capsules which consist of a combination of the active compounds with a base.
  • Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts.
  • suspensions of the active compounds as appropriate oily injection suspensions may be administered.
  • Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example ethyl oleate or triglycerides.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may also contain stabilizers.
  • the active ingredient may be contained in liposomes, pharmaceutical compositions in which the active ingredient is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers (hydrophobic).
  • the drug may be present both in the aqueous layer and in the lipidic layer (inside or outside) or, in any event, in the non-homogeneous system generally known as a liposomic suspension.
  • the hydrophobic layer generally but not exclusively, comprises phospholipids such as lecithin and sphingomycelin, steroids such as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.
  • the diameters of the liposomes generally range from about 15 nm to 5 microns.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula (I), wherein R1, and R2 are selected from the group consisting of hydrogen, lower alkyl, and lower alkylene, and R1 and R2 together with nitrogen can form a ring having from three to seven members; R3 and R4 are selected from the group consisting of hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, and halogen; ring A has from 5 to 8 carbon atoms; and pharmaceutically acceptable salts thereof, are useful as anticonvulsant agents for treating epilepsy.

Description

PIPERIDINE RING MODIFIED PHENCYCLIDINE ANALOGS AS
ANTICONVULSANTS
FIELD OF THE INVENTION The present invention relates to improvements in epilepsy therapy, and more particularly to compounds useful in the treatment of epilepsy and control of epileptic seizures.
BACKGROUND OF THE INVENTION Epilepsy is a disorder characterized by recurrent seizures, each of which consists of a sudden, excessive discharge of cerebral neurons resulting in transient neurological impairment. Seizures can affect a localized area of cerebral tissues, i.e. a partial seizure, or may involve wide areas of both cerebral hemispheres, i.e. a generalized seizure. Both types of seizures may be disabling and can have potentially serious consequences, although generalized seizures are more often associated with injury. Most patients are treated by chronic drug therapy and, in certain intractable cases, by surgical removal of the affected brain tissue. Drug treatment of epilepsy is intended to prevent the occurrence of seizures, but does not cure the underlying brain dysfunction. In practice, some patients obtain a complete relief from seizures, others experience a diminution in the frequency or severity of seizures, and some patients do not respond.
Approximately one percent of the general population is afflicted with epilepsy, and there are estimated to be approximately 360,000 Americans whose seizures are not controlled by presently available medications. Moreover, all currently used medications have undesirable side effects. Thus, there is a need for more effective and less toxic antiepileptic drugs.
Several drugs are currently in use for chronic prophylaxis against epileptic seizures. These compounds include phenobarbital, phenytoin, carbamazepine, primidone, valproic acid, ethosuximide, and clonazepam. Of these compounds, only the first four are effective and widely in use in the treatment of partial seizures. Valproic acid may be effective in treating partial seizures, although it is not approved or in widespread use for this treatment. All currently available antiepileptic drugs fail to control seizures in some patients. In those patients who respond, adverse drug effects may limit the patient to a suboptimal dose, or may prevent use of the drug. These adverse effects include dose dependent side effects and rare allergic or idiosyncratic reactions.
Each commonly used compound has a distinct profile of adverse effects. Phenobarbital may cause motor impairment including ataxia (unsteadiness), drowsiness, fatigue, and cognitive impairment. Phenytoin may cause ataxia, coarsening of the facial features, gingival hyperplasia, and hirsutism. Carbamazepine may cause ataxia, nausea and vomiting, and drowsiness. Primidone is metabolized to phenobarbital and phenylethylmalonamide, and has similar side effects to phenobarbital. In addition to these common side effects, all anticonvulsant drugs may cause rare idiosyncratic reactions, including serious blood and liver disorders, serious skin or integumentary disorders, or nerve damage (peripheral neuropathy).
Phencyclidine, commonly known as PCP, is currently a major drug of abuse in the United States. In recent years, it has received widespread attention because of the violent, homicidal and suicidal behavior of some of its users. Moreover, phencyclidine is one of the most fascinating psychotropic drugs, as the psychosis it elicits may provide the best available drug model of schizophrenia.
Godefroi et al., in U.S. Patent 3,097,136, disclose 1-phenylcyclohexylamine compounds of the formula
Figure imgf000005_0001
wherein R1 and R2 are hydrogen or alkyl radicals, the sura of the carbon atoms in the alkyl groups being less than 5, or wherein R1 and R2 together represent a polymethylene group containing 4 to 6 carbon atoms. These compounds are said to be useful for producing varying degrees of depression on the central nervous sys tem , such as euphoria , sedat ion , analges ia , and anesthesia. There is no disclosure that these compounds can be used as anticonvulsants. Hack et al . , in U .S . Patent 3 , 405 , 139 , disclose phenylcyclohexylalkylamine compounds of the formula
Figure imgf000006_0001
wherein R1 is hydrogen or lower alkyl, R2, R3, R4, R5, and R6 are hydrogen, halogen, hydroxyl, lower alkyl, aralkoxy, or alkoxy, and wherein two adjacent groups R2- R6 may together form a methylenedioxy group, X is lower alkylene which may be substituted by hydroxyl and/or keto groups and/or interrupted by a hetero atom, R7 is hydrogen or lower alkyl, and n is 2 or 3. The compounds are said to be coronary artery dilating agents.
Arvidsson et al., in U.S. Patent 4,426,386, disclose substituted phenyl piperidines of the formula:
Figure imgf000006_0002
wherein N is 1 or 3, Y is OH, R1COO-, R2R3NCOO-, or R4O, whereby R1 is an alkyl group or a possibly substituted phenyl group, R2 is an alkyl, phenethyl, benzyl, or phenyl group, R3 is H or an alkyl group, and R4 is an allyl or benzyl group, and R is an alkyl, hydroxyalkyl, dimethylaminoalkyl, or methylthioalkyl group or alkenyl group. The compounds are said to be useful for treatment of disorders in the central nervous system, and are said to have dopaminergic properties.
Lednicer, in U.S. Patents 4,113,866 and 4,447,454, discloses analgetic compounds of the formula
wherein R1 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms, CH2-alkenyl wherein alkenyl is from 2 to 4 carbon atoms, cycloalkyl of from 3 to 6 carbon atoms, cycloalkylmethyl of from 3 to 6 carbon atoms; R2 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms; Y is a variable consisting of alkyl of from 1 to 4 carbon atoms; R5 is a variable consisting of hydrogen and alkyl of from 1 to 4 carbon atoms; R4 is a variable consisting of alkyl of from 1 to 4 carbon atoms, CH2-alkenyl wherein alkenyl is of from 2 to 4 carbon atoms. The compounds are said to be useful in relieving pain in humans and animals.
Vignon et al., in European Journal of Pharmacology, 81 : 531-542 (1982), disclose compounds in the phencyclidine series which were used to study the method of binding of phencyclidine to receptors in the brain. However, there was no indication that any of the compounds disclosed could be used as anticonvulsants.
SUMMARY OF THE INVENTION
It is an object of the present invention to overcome deficiencies in the prior art, such as indicated above.
It is another object of the present invention to provide compounds which are effective anticonvulsants.
It is yet another object of the present invention to provide improvements in the treatment of epilepsy.
It is a further object of the present invention to provide anticonvulsant drugs that can beused with little or no neurotoxicity.
It has now been discovered that structural modification of phencyclidine [1-(1-phenylcyclohexyl)piperidine, alternatively known as PCP], a dissociative anesthetic compound, results in compounds that provide protection from seizures with little neurotoxicity.
The compounds of the present invention are modifications of PCP wherein the piperidine ring is modified, and have the following formulae:
wherein R1 and R2 may be hydrogen or lower alkyl, such as methyl, ethyl, propyl, isopropyl, or butyl or ( unsaturated) lower alkylene, or R1 and R2 may form with the nitrogen a three- to seven-membered ring with or without unsaturation, and R3 and R4 can be selected from the group consisting of hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, and halogen, i.e. chlorine, bromine or fluorine. In addition, ring A may be a ring of from 5 to 8 carbon atoms.
The compounds of the present invention have anticonvulsant activity and, at effective doses, no toxicity (ataxia) has been observed. The compounds of the present invention thus are superior to the presently available compounds for seizure prophylaxis in patients who fail to respond or who have unacceptable adverse reactions to presently available drugs.
The compounds of the present invention have been found to protect laboratory animals from seizures with little neurotoxicity. The compounds were active in the maximal electroshock (MES) test, which determines the ability of a compound to prevent the spread of seizures, and is therefore a test for efficacy against partial seizures, i.e. those that begin locally in an area of abnormal cerebral cortex and subsequently spread to adjacent areas, often resulting in a generalized seizure. Partial seizures are believed to be the most common type of seizure and to be responsible for many generalized seizures.
DETAILED DESCRIPTION OF THE INVENTION The compounds of the present invention are modifications of phencyclidine, compound I, below, and involve changes in the piperidine ring.
Figure imgf000010_0001
The compounds of the present invention can generally be described as follows:
Figure imgf000010_0002
wherein R1 and R2 may be hydrogen or lower alkyl, such as methyl, ethyl, propyl, isopropyl, or butyl, or (unsaturated) lower alkylene, or R1 and R2 may form a three-to-seven membered ring with nitrogen. R3 and R4 can be hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, or halogen (Cl, Br, or F). Additionally, ring A may contain from 5 to 8 carbon atoms. For example, phenylcycloheptylamines have been found to be particularly useful in treating epilepsy. The compounds of the present invention may be in the form of any pharmaceutically acceptable acid addition salt, i.e. any moiety which is non-toxic and makes the base compound soluble. Among these salts are hydrochloric acid, phosphoric acid, sulfuric acid, methanesulfonic acid, fumaric acid, and the like.
Alternatively, the base compound may be used.
EXAMPLE 1
Figure imgf000011_0001
Compound II was prepared by the addition of phenylmagnesium bromide to 1-(1-cyanocyclohexyl)-1,2,3,6-tetrahydropyridine. The 1-(1-cyanocyclohexyl)-1,2,3,6-tetrahydropyridine was prepared by the acid catalyzed condensation of cyclohexanone, 1,2,3,6-tetrahydropyridine and potassium cyanide. Compound II, but not its utility, is known from M. R. Kazlowski, R. G. Browne and F. J. Vinick, Pharmacology Biochemistry & Behavior 25: 1051-1058 (1986).
The hydrochloride salt of compound II is a free flowing white powder with a melting point of 217- 218ºC. The molecular weight of the hydrochloride of compound II is 278. EXAMPLE 2-9 (Compounds III - X)
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0003
Figure imgf000012_0004
Figure imgf000012_0005
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000013_0003
Compound III was prepared in a three step synthesis from 3-(R)methylcyclohexanone. Phenylmagnesium bromide was condensed with 3-(R)- methylcyclohexanone to give a mixture of isomeric tertiary alcohols. These alcohols were reacted with sodium azide in the presence of trifluoroacetic acid to give the corresponding 1-azido-1-phenyl-3-(R)- methylcyclohexanes. The azides were reduced to the tertiary amines, and compound III was separated from IV by crystallization of fumarate salt. The fumarate salt of compound III is a free flowing white powder with a melting point of 230-231°C and a molecular weight of 305.
Compounds V, VI and VII were prepared in a similar manner to that used for the preparation of compounds III and IV except that the appropriately substituted cyclohexanones were used as starting materials.
Compound VIII was prepared in a three step synthesis from cyclohexanone. 3-Methylphenylmagnesium bromide was condensed with cyclohexanone to give 1-(3-methylphenyl)cyclohexanol which in turn was reacted with sodium azide in the presence of trifluoroacetic acid to give the corresponding 1-azido-1-(3-methylphenyl)cyclohexane. The azide was then reduced to the tertiary amine VIII.
Compound IX was prepared by nitration of compound I with nitric acid according to the method of P. Y. Johnson, R. Pan, J. Q. Wen and C. J. Halfman, J. Org. Chem. 46: 2049-2054 (1981).
Compound X was prepared in the same manner as III except that cycloheptanone was used as the starting material instead of 3-(R)-methylcyclohexanone.
The above compounds prevented maximal electroshock (MES) seizures in mice. However, in contrast to phencyclidine, which causes neurotoxicity as determined by the mouse rotorod ataxia test, compounds II and III did not cause measurable toxicity at the effective anticonvulsant doses. These data are presented in Table I. TABLE 1
Seizure Protectant Effect and Toxicity of Piperidine Ring Modified PCP Analogs and Related Compounds
COMPOUND DOSE SEIZURE PROTECTION TOXICITY
(mg/kg) (MES) (rotorod)
II 10 2/4 0/4
III 3 1/4 0/4
III 10 4/4 0/4
IV 100 3/3 4/8
V 30 1/1 2/4
VI 30 1/1 1/4
VII 100 3/3 2/8
VIII 10 1/4 0/4
IX 30 1/1 0/4
X 10 1/4 0/4
30 1/4 0/4
DEXOXADROL* 10 2/4 3/4
LEVOXADROL** 30 0/1 0/4
X . . . 1-phenylcycloheptylamine
IX . . . 1- [1-(3-nitrophenylcyclohexyl]piperidine Mice were injected intraperitoneally with the drugs indicated (dissolved in aqueous 0.9% sodium chloride solution) and tested 30 min later. Seizure protection indicates number of animals failing to exhibit hind-limb tonic extension in response to a 200 msec electrical stimulus (50 mA; 60 Hz) applied via corneal electrodes primed with 0.9% sodium chloride solution. Animals not treated with the vehicle solution ("control animals") all exhibit hind-limb extension. Toxicity indicates number of animals unable to maintain equilibrium for 1 min when placed on a knurled rod rotating at 6 revolutions per min. Control animals are all able to maintain equilibrium. Data is expressed as number of animals showing effect/total number of animals tested.
*Data for this compound which is pharmacologically similar to compound I (phencyclidine) is shown for comparison.
**This is the optical enantiomer of dexoxadrol which lacks PCP-like activity and serves as a control. Table 2 shows toxic doses and doses of Compounds II, VI, and VIII.
TABLE 2
COMPOUND ED50 TD50
(mg/kg) (mg/kg)
II 5 6 VI 15 80 VIII 12 34
The toxic dose (TD50) for 50% of animals at the peak of the toxic effect, and the MES protective dose (ED50) for 50% of the animals at the peak of the seizure protective effect were determined by probit analysis. The date are reported in mg/kg.
The compounds of the present invention may be administered as the bases, or may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" is intended to include salts with pharmaceutically acceptable acids such as hydrochloric, sulfuric, acetic, phosphoric, methanesulfonic, fumaric, and the like.
Pharmaceutical compositions for treating epilepsy or other convulsions within the scope of the present invention include compositions wherein the active ingredient compound is contained in an effective amount to achieve its intended purpose. Determination of the effective amount is, of course, within the skill of the art. However, the compounds of the present invention are generally effective in preventing seizures when administered in dosaσes of from about 1 mg/kg of body weight to about 100 mg/kg of body weight, it being understood that individual dosages will vary with the individual response of the patient.
In addition to the phencyclidine derivatives of the present invention, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Preferably, the preparations, particularly those which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, contain from about 0.1 to about 99 percent ,by weight of active ingredient, together with the excipient.
The pharmaceutical preparations of the present invention are manufactured in a conventional manner, for example, by means of conventional mixing, granulating, dragee-making, or dissolving processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired or necessary to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using for example maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone.
If desired, disintegrating agents may be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Slow or extended release compositions may also be formulated.
Auxiliaries include flow-regulating agents and lubricants, such as silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, may be resistant to gastric juices. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum Arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetyl-cellulose phthalate or hydroxypropylmethylcellulose phthalate, are used. Dyestuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize different combinations of active compound doses.
Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
Pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triclycerides, paraffin hydrocarbons, polyethylene glycols, and higher alkanols. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
Alternatively, the active ingredient may be contained in liposomes, pharmaceutical compositions in which the active ingredient is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers (hydrophobic). The drug may be present both in the aqueous layer and in the lipidic layer (inside or outside) or, in any event, in the non-homogeneous system generally known as a liposomic suspension.
The hydrophobic layer, generally but not exclusively, comprises phospholipids such as lecithin and sphingomycelin, steroids such as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature. The diameters of the liposomes generally range from about 15 nm to 5 microns.
While the invention is described above in relation to certain specific embodiments, it will be understood that many variations are possible, and that alternative materials and reagents can be used without departing from the invention. In some cases such variations and substitutions may require some experimentation, but such will only involve routine testing.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and therefore such adaptations and modifications are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula
Figure imgf000021_0001
wherein R1 and R2 are selected from the group consisting of hydrogen, lower alkyl and lower alkylene, or R1 and R2 together with nitrogen form a ring having from three to seven members; R3 and R4 are selected from the group consisting of hydrogen, lower alkyl, lower alkylene, hydroxy, methoxy, amino, alkylamino, thio, thioalkyl, chlorine, bromine, or fluorine; ring A has from 5 to 8 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that R2-N-R, is not a 3,4-dehydro piperidine ring.
2. A compound according to claim 1 having the formula:
Figure imgf000021_0002
3. A method for treating epilepsy comprising administering to a patient afflicted with epilepsy an effective amount for at least partially controlling seizures of a compound according to claim 1.
4. The method of claim 3 wherein the compound has the formula:
Figure imgf000022_0001
5. The method of claim 3 wherein the compound has the formula:
Figure imgf000022_0002
6. A composition for treating epilepsy comprising an effective amount for at least partially controlling seizures of a compound according to claim 1 and a pharmaceutically acceptable carrier.
7. The composition of claim 6 wherein the compound has the formula
Figure imgf000023_0001
8. The composition of claim 7 wherein the compound has the formula:
Figure imgf000023_0002
PCT/US1989/001229 1988-03-25 1989-03-22 Piperidine ring modified phencyclidine analogs as anticonvulsants WO1989009209A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US172,922 1980-07-28
US17292288A 1988-03-25 1988-03-25

Publications (1)

Publication Number Publication Date
WO1989009209A1 true WO1989009209A1 (en) 1989-10-05

Family

ID=22629762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/001229 WO1989009209A1 (en) 1988-03-25 1989-03-22 Piperidine ring modified phencyclidine analogs as anticonvulsants

Country Status (3)

Country Link
AU (1) AU3366389A (en)
CA (1) CA1329808C (en)
WO (1) WO1989009209A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB836083A (en) * 1957-09-19 1960-06-01 Parke Davis & Co Heterocyclic amine compounds
GB853775A (en) * 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
US3097136A (en) * 1960-04-04 1963-07-09 Parke Davis & Co Process for producing a depressant-like effect on the central nervous system
US3097207A (en) * 1958-03-06 1963-07-09 Parke Davis & Co 1-halophenyl and 1-alkoxyphenyl cyclohexylamines
US3145229A (en) * 1960-04-04 1964-08-18 Parke Davis & Co Process for the production of nu-substituted-1-phenylcyclohexylamines
US3192219A (en) * 1960-04-04 1965-06-29 Parke Davis & Co Process for producing certain new 1-phenylcyclohexylamine compounds
US3209006A (en) * 1959-05-01 1965-09-28 May & Baker Ltd Phenylpiperidine and phenyltetrahydropyridine compounds
US3634454A (en) * 1968-05-14 1972-01-11 Reckitt & Colmann Prod Ltd Derivatives of pyrrolidine
US3652769A (en) * 1969-10-01 1972-03-28 Merck & Co Inc Cycloalkylamines in the treatment of mental disorders involving depression and compositions therefor
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US4460604A (en) * 1976-06-03 1984-07-17 The Upjohn Company 4-Amino-4-aryl-cyclohexanones
US4767790A (en) * 1981-04-06 1988-08-30 The Boots Company Plc Therapeutic agents

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB836083A (en) * 1957-09-19 1960-06-01 Parke Davis & Co Heterocyclic amine compounds
GB853775A (en) * 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
US3097207A (en) * 1958-03-06 1963-07-09 Parke Davis & Co 1-halophenyl and 1-alkoxyphenyl cyclohexylamines
US3209006A (en) * 1959-05-01 1965-09-28 May & Baker Ltd Phenylpiperidine and phenyltetrahydropyridine compounds
US3097136A (en) * 1960-04-04 1963-07-09 Parke Davis & Co Process for producing a depressant-like effect on the central nervous system
US3145229A (en) * 1960-04-04 1964-08-18 Parke Davis & Co Process for the production of nu-substituted-1-phenylcyclohexylamines
US3192219A (en) * 1960-04-04 1965-06-29 Parke Davis & Co Process for producing certain new 1-phenylcyclohexylamine compounds
US3634454A (en) * 1968-05-14 1972-01-11 Reckitt & Colmann Prod Ltd Derivatives of pyrrolidine
US3652769A (en) * 1969-10-01 1972-03-28 Merck & Co Inc Cycloalkylamines in the treatment of mental disorders involving depression and compositions therefor
US4460604A (en) * 1976-06-03 1984-07-17 The Upjohn Company 4-Amino-4-aryl-cyclohexanones
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US4767790A (en) * 1981-04-06 1988-08-30 The Boots Company Plc Therapeutic agents

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 108, (1988), Columbus, Ohio, U.S.A., BRADY et al.: "Mechanism-based inhibition of cytochrome P-450 by heterocyclic analogs of phencyclidine", see col. 2, pg. 15, the abstract No. 15780b, DRUG METAB. DISPOS. (1987), 15(5), 648-52 (Eng). *
CHEMICAL ABSTRACTS, Vol. 54, (1960), Columbus, Ohio, U.S.A.: "Heterocyclic Amines", see 24827h-24328b.; & GB,A,836083, 1 June 1960. *
CHEMICAL ABSTRACTS, Vol. 68, (1968), Columbus, Ohio, U.S.A., DELL et al.: "Methyl-substituted cyclohexane derivatives. II. Alykl-substituted l-arylcyclohexylamino-alkyl tertiary amines", see col. 2, pg. 3799 - col. 1, pg. 3800, the abstract No. 39213a, ARCH. PHARM. (Weinheim) 300 (11), 933-9 (1967) (Ger). *
CHEMICAL ABSTRACTS, Vol. 69, (1968), Columbus, Ohio, U.S.A., YOSHIKAWA: "1-Secondary (or tertiary)-amino-1-phenylcyclo-hexanes", see col. 2, p. 963, the abstract No. 10195f.; & JP,B,42 019 087, ('67), 28 September 1967. *
CHEMICAL ABSTRACTS, Vol. 77, (1972), Columbus Ohio, U.S.A., STEVENS et al.: "Epoxyamines III. Synthesis and reactions of 2-(1-aziridinyl)-2-phenyl-3,3-dimethyl-oxirane and 2-(1-aziridinyl)-2-phenyl-1-oxaspiro (2.4) heptane", See col. 1, pg. 383, the abstract No. 151756s, J. ORG. CHEM. (1972), 37(20), 3130-3 (Eng). *
CHEMICAL ABSTRACTS, Vol. 78, (1973), Columbus, Ohio, U.S.A., RAVINA et al.: "Synthesis of trichloromethyl analogs of phenylcyclidine with potential central nervous system depressant activity", see col. 1, pg. 502, the abstract No. 58210u, AM. REAL. ACAD. FARM. (1972), 38(2), 301-12 (Span). *
CHEMICAL ABSTRACTS, Vol. 83, (1975), Columbus, Ohio, U.S.A., BOEHME et al.: "Reaction of iminium salts with arylmagnesium halides", see col. 1, p. 373, the abstract No. 206051q, CHEM. BER. (1975) 108(9), 2827-33 (Ger). *
CHEMICAL ABSTRACTS, Vol. 84, (1976), Columbus, Ohio, U.S.A., GENESTE et al.: "New Synthesis of isomers of l-phenylcyclo-hexylamines substituted on the cyclohexane ring", see col. 1-2, p. 429, the Abstract No. 74051y, BULL. SOC. CHIM. FR. (1975), (7-8, Pt. 2), 1619-26 (Fr). *
CHEMICAL ABSTRACTS, Vol. 97, (1982), Columbus, Ohio, U.S.A., RISNER: "Intravenous self-administration of phencyclidine and related compounds in the dog", See col. 2, pg. 49, the abstract No. 104117n. J. PHARMACOL. EXP. THER. 1982, 221(3), 637-44 (Eng). *
EUROPEAN JOURNAL OF PHARMACOLOGY, Vol. 81, 1982, VIGNON et al.: "Biochemical Properties of the Brain Phencyclidine Receptor", pp. 531-542. *
J. ORG. CHEM., Vol. 46, 1981, JOHNSON et al.: "Synthesis of Amine Derivatives of Phencyclidine", pp. 2049-2054. *
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, Vol. 25, 1986, KOZLOWSKI et al.: "Discriminative Stimulus Properties of Phencyclidine (PCP)- Related Compounds, etc". pp. 1051-1058. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists

Also Published As

Publication number Publication date
AU3366389A (en) 1989-10-16
CA1329808C (en) 1994-05-24

Similar Documents

Publication Publication Date Title
KR940010764B1 (en) Process for the preparation of phenyl carbamates
CN100457731C (en) Benzamide modulators of metabotropic glutamate receptors
Robertson et al. The treatment of Gilles de la Tourette syndrome by limbic leucotomy.
US6649607B2 (en) Compositions and methods for treating or preventing convulsions or seizures
PL190218B1 (en) Derivatives of 5h-thiazole[3,2-a]pyrimidine, method of obtaining them and medicine containing such derivatives
EP1893193A2 (en) Use of brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
DE69727806T2 (en) 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE
CA2433039C (en) Agent for therapeutic and prophylactic treatment of neuropathic pain
KR20030053475A (en) 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinic receptor antagonists
WO1989009209A1 (en) Piperidine ring modified phencyclidine analogs as anticonvulsants
PL199587B1 (en) 1−cyclic amino−alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants
Leslie et al. Some pharmacological properties of thioproperazine and their modification by anti‐Parkinsonian drugs
EP0694299B1 (en) The use of( a) bicycloheptane derivative(s)
EP0900082B1 (en) Use of pyridyl- and pyrimidyl-piperazines for the manufacture of a medicament for the treatment of substance abuse disorders
JPH0623105B2 (en) Pharmaceutical composition for the treatment of epileptic seizures
US6420416B2 (en) Method of treating epilepsy
US4514403A (en) Hydrouracil compounds
Chatterjie et al. Prevention of cocaine-induced hyperactivity by a naloxone isomer with no opiate antagonist activity
EP0430035B1 (en) Use of benzothiazepine for the preparation of a medicament for treating seizures
US5196415A (en) 5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of epilepsy and cocaine addiction
DE69214205T2 (en) New isatine oxime derivatives, their production and use
MULLEN et al. Adrenergic blocking agents in treatment of glaucoma
JP2001512124A5 (en)
WO1995019173A1 (en) Pharmaceutical compositions
DE69918671T2 (en) OPTICAL PAPILLAR CIRCULATION IMPROVING MEDIUM

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE